Effect of combined therapy using balloon-ocluded arterial infusion of cisplatin with concurrent radiation for locally invasive bladder cancer: multi-center study

Effect of combined therapy using balloon-ocluded arterial infusion of cisplatin with concurrent radiation for locally invasive bladder cancer: multi-center study - Effect of chemotherapy using cisplatin with concurrent radiation for locally invasive bladder cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002508

Enrollment

220

Registered

2009-09-17

Start date

2009-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bladder cancer

Interventions

BOAI-CDDP arterial infusion + radiation Dose: CDDP 100mg x 1 + radiation 60Gy follow up duration: 5 years Radical cystectomy with/without neoadjuvant or adjuvant chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) patients who or whose family can agree with written informed consent (2) patients with bladder cancer which is histologivally comfirmed urothelial cancer (3) cTNM classification: T2-T3, N0, M0 (4) performance status: PS 0-2 (ECOG) (5) patients who meet the following criteria 1. liver function; AST less than 2.5 times of the institutional upper limit of the normal range, total bilirubin less than; 2.0 times of the institutional upper limit of the normal range, 2. renal function; creatinin less than 1.5mg/dL, 3.cardiac function; tolerable function for the therapy, 4. bone-marrow; WBC more than 3,000/microL, neutrophil more than 1,500/microL, hemoglobin more than 10g/dL, platelet more than 100,000/microL, (6) regardless of age.

Exclusion criteria

Exclusion criteria: (1) Previous general treatment (radiation or chemotherapy) for the patients with bladder cancer. (2) Patients who have severe complication (including serious diabetes) unable to be eligible for the study. (3) Patients having another active cancer. (4) Pregnant women, breast-feeding women, or women who will get pregnant. (5) Others who are considered to be a ineligible for the study.

Design outcomes

Primary

Measure	Time frame
progression free survival	—

Countries

Japan

Contacts

Public ContactHideki Enokida

Graduate School of Medical and Dental Sciences, Kagoshima University Department of Urology

enokida@m.kufm.kagoshima-u.ac.jp099-275-5395

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026